Solaraze U.S. Autumn Launch Likely After Bioglan Purchase From SkyePharma
Executive Summary
Bioglan Pharma is projecting an August/September launch in North America for its actinic keratoses product Solaraze (diclofenac gel, 3%) following a licensing agreement with SkyePharma.
You may also be interested in...
SkyePharma Solaraze
Diclofenac gel, 3%, approved for actinic keratoses Oct. 16. The company is in discussions with a potential North American marketing partner. The gel should be applied to lesion areas twice daily; the recommended duration of therapy is from 60 to 90 days. The NDA (21-005) was filed Oct. 22, 1998
Dura To Recruit 60 Reps For Glaxo Derm Line; Four Products Are Off-Patent
Dura will promote Glaxo's dermatology product line through the establishment of a 60-sales rep dermatology sales force, the company said in an Oct. 2 conference call.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011